{"id":40139,"date":"2022-04-16T18:02:42","date_gmt":"2022-04-16T18:02:42","guid":{"rendered":"https:\/\/www.sisinternational.com\/?page_id=40139"},"modified":"2026-05-05T16:21:18","modified_gmt":"2026-05-05T20:21:18","slug":"marktforschung-zur-wundversorgung","status":"publish","type":"page","link":"https:\/\/www.sisinternational.com\/de\/losungen\/marktforschung-im-gesundheitswesen-2\/marktforschung-zur-wundversorgung\/","title":{"rendered":"Wound Care Market Research: Clinician-Led Strategy"},"content":{"rendered":"
\n

Marktforschung zur Wundversorgung<\/h1>\n<\/p>\n
\"SIS<\/figure>\n<\/p>\n
\n

Kleinere Wunden und Verletzungen k\u00f6nnen wir mit Erster Hilfe zu Hause behandeln. Manche sind gr\u00f6\u00dfer oder tiefer als andere. Au\u00dferdem brauchen solche Schnitte einen Arzt, der sie heilen l\u00e4sst und Infektionen vorbeugt. Das Wundzentrum ist eine weitere medizinische Einrichtung zur Behandlung von Wunden, die nicht heilen. Haben Sie eine Verletzung, die zwei Wochen alt ist und keine Anzeichen der Heilung zeigt? Dann w\u00e4re es hilfreich, wenn Sie in die Wundklinik gehen w\u00fcrden. Eine sechs Wochen alte Wunde, die noch nicht vollst\u00e4ndig verheilt ist, ist chronisch. Eine solche Wunde braucht weitere Versorgung durch die Wundklinik.<\/p>\n

Warum ist Wundpflege wichtig?<\/h2>\n

Wenn Menschen ihre Wunden oder Geschw\u00fcre nicht pflegen, kann dies zu einem ernsthaften Gesundheitsproblem werden. Wunden sind entweder akut oder chronisch. Eine chronische Wunde zeigt nach vier bis sechs Wochen keine Anzeichen der Heilung. Wenn Wunden nicht heilen, k\u00f6nnen sie zu Infektionen, Schmerzen, Behinderungen und sogar Amputationen f\u00fchren. Wir d\u00fcrfen die Bedeutung der Wundpflege nicht untersch\u00e4tzen. Solange eine chronische Wunde unbehandelt bleibt, besteht die Gefahr einer Infektion.<\/p>\n<\/div>\n

Wound Care Market Research: How Leading Manufacturers Win Clinician Preference<\/h1>\n

Wound care is a clinician-led category. The nurse at the bedside, not the procurement contract, decides which dressing comes off the cart. Manufacturers who understand this win share. Those who optimize for hospital formulary alone leave growth on the table.<\/p>\n

The category rewards specificity. Antimicrobial dressings, negative pressure wound therapy, collagen matrices, and skin substitutes each follow different adoption logics. Wound care market research that treats them as one segment produces generic insight. Research that isolates the decision maker, the wound type, and the care setting produces commercial advantage.<\/p>\n

Why Wound Care Market Research Rewards Clinician-Level Depth<\/h2>\n

The prescriber in wound care is rarely the physician of record. Wound ostomy continence nurses (WOCNs), wound care directors, and nurse practitioners drive product selection in long-term care, home health, and hospital outpatient departments. They build treatment outlines based on exudate level, bioburden, periwound condition, and healing trajectory. They escalate to silver, iodine, or PHMB antimicrobials when stalled wounds show biofilm signatures.<\/p>\n

SIS International’s structured expert interviews with wound care nurses and WOCNs across U.S. acute and post-acute settings indicate that antimicrobial dressing selection is governed less by brand preference than by a two-week trial-and-escalate protocol tied to wound bed appearance.<\/span> Manufacturers who map their value story to that escalation logic enter the consideration set. Those who lead with mechanism-of-action claims disconnected from the clinician’s decision sequence get filtered out before sampling.<\/p>\n

This is why surveys alone underperform in wound care. The decision is tactile and visual. Clinicians evaluate conformability, exudate handling, atraumatic removal, and wear time at the dressing change. Concept tests without product-in-hand evaluation miss the variables that actually drive switching.<\/p>\n

The Four Decision Axes That Shape Wound Care Adoption<\/h2>\n

Effective wound care market research isolates four axes that determine commercial uptake. Each carries different evidence requirements and different KOL mapping needs.<\/p>\n

\n\n\n\n\n\n\n\n\n
Decision Axis<\/th>\nPrimary Decision Maker<\/th>\nEvidence That Moves the Decision<\/th>\n<\/tr>\n<\/thead>\n
Antimicrobial selection<\/td>\nWOCN, wound care director<\/td>\nBiofilm disruption data, wear time, periwound tolerability<\/td>\n<\/tr>\n
Advanced therapy escalation<\/td>\nVascular surgeon, podiatrist<\/td>\nHealing trajectory at four weeks, reimbursement coverage<\/td>\n<\/tr>\n
Formulary inclusion<\/td>\nValue analysis committee<\/td>\nTotal cost per healed wound, nurse time savings<\/td>\n<\/tr>\n
Home health adoption<\/td>\nAgency clinical director, payer<\/td>\nVisit reduction, caregiver simplicity, supply logistics<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Source: SIS International Research<\/em><\/p>\n

Manufacturers often build a single launch narrative across all four. The narrative collapses on contact with the value analysis committee, which speaks the language of cost per healed wound, not clinical novelty. It also collapses with the home health agency, which optimizes for nurse visits per episode under PDGM reimbursement.<\/p>\n

What Patient Journey Mapping Reveals in Chronic Wound Categories<\/h2>\n

Diabetic foot ulcers, venous leg ulcers, and pressure injuries each follow distinct referral and reimbursement pathways. A diabetic foot ulcer patient may pass through primary care, podiatry, vascular surgery, and a wound center within a single episode. Each handoff is a product decision point. Each clinician operates under different incentives.<\/p>\n

Patient journey mapping in wound care identifies where products enter, exit, and get switched. It also surfaces the abandonment points. Across SIS International’s qualitative work with U.S. wound care clinicians, a recurring pattern emerges: products selected in the wound center are frequently substituted within seven to fourteen days of home health transition because the home agency stocks a different formulary.<\/span> Manufacturers who fail to model the cross-setting handoff lose volume they assumed they had won.<\/p>\n

This is where real-world evidence and claims-linked analysis complement primary qualitative work. The clinician interview reveals the why. The claims data reveals the where and how often. Together they shape a payer value story that addresses cost per healed wound across the full episode rather than the single dressing change.<\/p>\n

How Leading Manufacturers Build Launch Sequencing for Advanced Modalities<\/h2>\n

Skin substitutes, cellular and tissue-based products, and negative pressure wound therapy operate under reimbursement structures that change adoption math entirely. CMS coverage decisions, the LCD for cellular and tissue products, and the transition of skin substitutes to ASP-based reimbursement reshape which products get used and where. Indication prioritization matters here. A product cleared for diabetic foot ulcers and venous leg ulcers may see ninety percent of its volume in one indication based on reimbursement and KOL endorsement, not clinical breadth.<\/p>\n

Launch sequencing should follow the reimbursement gradient. Hospital outpatient departments and wound centers with established billing infrastructure absorb advanced modalities first. Physician offices follow. Home health is last because payment models lag. Manufacturers who launch broadly and uniformly burn commercial spend on accounts that cannot yet bill the product profitably.<\/p>\n

The SIS Approach to Wound Care Market Research<\/h2>\n

SIS International conducts wound care market research through B2B expert interviews with WOCNs, wound care directors, vascular surgeons, podiatrists, and home health clinical leaders, paired with concept and product evaluation sessions that put the dressing in the clinician’s hands. This combination surfaces the prescription behavior, the escalation triggers, and the tactile evaluation that drive switching. It also tests the payer value story against the value analysis committee logic before launch.<\/p>\n

SIS International’s proprietary research in antimicrobial wound care indicates that clinicians evaluate new dressings against a mental benchmark of their current go-to product, and that benchmark shifts only when the new product demonstrates a clear advantage on either wear time, exudate handling, or atraumatic removal.<\/span> Generic superiority claims do not move the benchmark. Specific, clinician-relevant proof points do.<\/p>\n

The firms that grow share in wound care invest in clinician-level intelligence before committing to launch sequencing, KOL mapping, and formulary positioning. Wound care market research conducted at that depth turns a crowded category into a defensible position.<\/p>\n

\u00dcber SIS International<\/h2>\n

SIS International<\/a> bietet quantitative, qualitative und strategische Forschung an. Wir liefern Daten, Tools, Strategien, Berichte und Erkenntnisse zur Entscheidungsfindung. Wir f\u00fchren auch Interviews, Umfragen, Fokusgruppen und andere Methoden und Ans\u00e4tze der Marktforschung durch. Kontakt<\/a> f\u00fcr Ihr n\u00e4chstes Marktforschungsprojekt.<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<\/p>\n

\n

Related SIS Resources<\/h3>\n